Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Starbucks (SBUX) concluded the recent trading session at $86.81, signifying a -4.83% move from its prior day's close.

Starbucks' (NASDAQ: SBUX | SBUX Price Prediction) stock is down 10% in the last year, while the S&P 500 is 12% higher.

This column recently noted that former Starbucks Chairman and CEO Howard Schultz has relocated to Florida, which has no individual income tax, from Washington, where politicians are attempting to create an individual income tax in defiance of the state constitution.

SBUX targets $2B in cost savings over two years, aiming to boost efficiency and support margin recovery amid ongoing investments.

Starbucks continues to struggle operationally and financially despite new leadership and the 'Back to Starbucks' transformation plan. Operational issues—long lines, inconsistent quality, and unclean stores—have eroded margins, with operating profits dropping from near 20% to below 8%. 2025 sales grew nearly 3% to $37.2B, but GAAP earnings halved to $1.63/share, and adjusted earnings fell to $2.13/share, below the dividend payout.

Starbucks (SBUX +1.39%) stock is outperforming broad market indexes in 2026.

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses. About one in every eight U.S. adults is currently taking a GLP-1 drug, like Ozempic or Zepbound, according to the KFF Health Tracking Poll.